A BILL 
To expand certain securities exemptions to respond to 
COVID–19, to establish an X-prize for creating an effec-
tive COVID–19 vaccine, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Crowdfunding to Com-
4
bat the Coronavirus Act’’. 
5
00:38 Mar 27, 2020
H6253
2 
•HR 6253 IH
SEC. 2. EXPANSION OF CERTAIN SECURITIES EXEMPTIONS 
1
TO RESPOND TO COVID–19. 
2
(a) DEFINITIONS.—Section 2(a) of the Securities Act 
3
of 1933 (15 U.S.C. 77b(a)) is amended by adding at the 
4
end the following: 
5
‘‘(20) 
ISSUER
COMBATING
COVID–19.—The 
6
term ‘issuer combating COVID–19’ means an issuer 
7
that undertakes— 
8
‘‘(A) efforts to find a vaccine for COVID– 
9
19; 
10
‘‘(B) research or production of medical 
11
equipment related to COVID–19, including— 
12
‘‘(i) testing equipment; and 
13
‘‘(ii) touchless automation and hands- 
14
free proximity sensing technology; 
15
‘‘(C) research or production of technology 
16
or equipment related to social distancing or 
17
other non-medical strategies to reduce the dan-
18
ger of COVID–19 to the general population, in-
19
cluding— 
20
‘‘(i) online education technology; and 
21
‘‘(ii) remote video conferencing tech-
22
nology; and 
23
‘‘(D) such other activities as the Commis-
24
sion may determine appropriate.’’. 
25
00:38 Mar 27, 2020
H6253
3 
•HR 6253 IH
(b) ISSUE EXEMPTIVE AUTHORITY WITH RESPECT 
1
TO COVID–19.—Section 3(b) of the Securities Act of 
2
1933 (15 U.S.C. 77c(b)) is amended— 
3
(1) in paragraph (1), by inserting after ‘‘no 
4
issue of securities’’ the following: ‘‘(other than an 
5
issue of securities by an issuer combating COVID– 
6
19)’’; and 
7
(2) in paragraph (2)(A), by striking ‘‘The ag-
8
gregate’’ and inserting ‘‘Except for securities of an 
9
issuer combating COVID–19, the aggregate’’. 
10
(c) CROWDFUNDING EXEMPTION WITH RESPECT TO 
11
COVID–19.—Section 4(a)(6)(A) of the Securities Act of 
12
1933 (15 U.S.C. 77d(a)(6)(A)) is amended by inserting 
13
before ‘‘the aggregate amount’’ the following: ‘‘except for 
14
transactions involving the offer or sale of securities by an 
15
issuer combating COVID–19,’’. 
16
(d) EXEMPTION FROM JOINT AND SEVERAL LIABIL-
17
ITY.—Section 24 of the Securities Act of 1933 (15 U.S.C. 
18
77x) is amended by adding at the end the following: ‘‘Not-
19
withstanding any other provision of law, an issuer com-
20
bating COVID–19 shall not be subject to joint and several 
21
liability for any claim against such issuer, other than a 
22
claim of fraud under the securities laws.’’. 
23
00:38 Mar 27, 2020
H6253
4 
•HR 6253 IH
SEC. 3. COVID–19 X-PRIZE. 
1
If the Director of the Centers for Disease Control and 
2
Prevention or the Director of the National Institutes of 
3
Health determines that a person has created a vaccine for 
4
COVID–19 that cuts the incidence and mortality rate of 
5
COVID–19 by more than 50 percent and makes such vac-
6
cine widely available to the public at affordable rates, such 
7
Director shall report such determination to the President 
8
and the Secretary of the Treasury. If, after reviewing such 
9
report, the President agrees, the Secretary of the Treasury 
10
shall, without further appropriation and out of any 
11
amounts in the general fund not otherwise appropriated, 
12
pay such person $1,000,000,000. 
13
SEC. 4. GAO STUDY. 
14
Not later than 1 year after the date of the enactment 
15
of this Act, the Comptroller General of the United States 
16
shall submit to Congress a study on the impact of this 
17
Act and the amendments made by this Act. 
18
SEC. 5. SUNSET. 
19
This Act and the amendments made by this Act shall 
20
have no force or effect after the earlier of— 
21
(1) the date the Secretary of the Treasury 
22
awards the prize described under section 3; and 
23
(2) the end of the 3-year period beginning on 
24
the date of enactment of this Act. 
25
Æ 
00:38 Mar 27, 2020
H6253
